Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US88032L6056
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG000BJ6R36
TENX

Tenax Therapeutics, Inc.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Tenax Therapeutics, Inc.
ISIN
US88032L6056
TICKER
TENX
MIC
XNAS
REUTERS
TENX.OQ
BLOOMBERG
TENX US
Tue, 03.11.2026       Tenax Therapeutics

Lead Plaintiff Deadline: December 28, 2026. Investors who purchased (NASDAQ: TENX) securities between November 13, 2023 and August 7, 2026 may be eligible to recover losses.New York, New York--(Newsfile Corp. - November 3, 2026) - This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behal...
Tue, 03.11.2026       Tenax Therapeutics

Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) is the subject of a securities fraud class action lawsuit filed on behalf of investors who purchased or otherwise acquired the Company's securities from November 13, 2023 through August 7, 2026, inclusive. The Law Offices of Howard G. Smith today reported the lawsuit, Katz v. Tenax...
Tue, 03.11.2026       Tenax Therapeutics

A securities fraud class action lawsuit has been filed against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) on behalf of investors who purchased or otherwise acquired the Company's securities between November 13, 2023 and August 7, 2026, inclusive. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced the filing. T...
Tue, 03.11.2026       Tenax Therapeutics

New York, New York--(Newsfile Corp. - November 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Tenax Therapeutics, Inc. (NASDAQ: TENX) between November 13, 2023 and August 7, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has a...
Mon, 02.11.2026       Tenax Therapeutics

A securities class action lawsuit has been filed against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) on behalf of investors who purchased or otherwise acquired Tenax Therapeutics, Inc. securities from November 13, 2023 to August 7, 2026, inclusive. The Law Offices of Frank R. Cruz today reported the case, Katz v. Tenax Therap...
Mon, 02.11.2026       Tenax Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Tenax To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Tenax between November 13, 2023 and August 7, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh...
Mon, 02.11.2026       Tenax Therapeutics

New York, New York--(Newsfile Corp. - November 2, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) on behalf of investors that purchased or otherwise acquired Tenax securities between November 13, 2023 and August 7, 2026 (the "Clas...
Mon, 02.11.2026       Tenax Therapeutics

New York, New York--(Newsfile Corp. - November 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Tenax Therapeutics, Inc. (NASDAQ: TENX) between November 13, 2023 and August 7, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has alread...
Sun, 01.11.2026       Tenax Therapeutics

New York, New York--(Newsfile Corp. - October 31, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Tenax Therapeutics, Inc. (NASDAQ: TENX) between November 13, 2023 and August 7, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has alread...
Sat, 31.10.2026       Tenax Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Tenax To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Tenax between November 13, 2023 and August 7, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh...
Silent Ad
Sat, 31.10.2026       Tenax Therapeutics

New York, New York--(Newsfile Corp. - October 30, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Tenax Therapeutics, Inc. (NASDAQ: TENX) between November 13, 2023 and August 7, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has alread...
Fri, 30.10.2026       Tenax Therapeutics

Investors who lost money on Tenax Therapeutics, Inc. ("Tenax" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Tenax Therapeutics, Inc. (NASDAQ: TENX) investors into whether the Company may have violated the federal securi...
Fri, 30.10.2026       Tenax Therapeutics

Investors who suffered losses on Tenax Therapeutics, Inc. ("Tenax" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Tenax Therapeutics, Inc. (NASDAQ: TENX) investors into whether the Company may have violated the fe...
Fri, 30.10.2026       Tenax Therapeutics

New York, New York--(Newsfile Corp. - October 29, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) on behalf of investors that purchased or otherwise acquired Tenax securities between November 13, 2023 and August 7, 2026 (the "Clas...
Fri, 30.10.2026       Tenax Therapeutics

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Tenax Therapeutics, Inc. (NASDAQ: TENX) securities between November 13, 2023 and August 7, 2026, inclusive (the “Class Period”), have until December 28, 2026 to seek appointment as lead plaintiff of the Tenax Therapeutics class action lawsuit. Captioned K...
Fri, 30.10.2026       Tenax Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Tenax To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Tenax between November 13, 2023 and August 7, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh...
Thu, 29.10.2026       Tenax Therapeutics

New York, New York--(Newsfile Corp. - October 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Tenax Therapeutics, Inc. (NASDAQ: TENX) between November 13, 2023 and August 7, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has a...
Thu, 29.10.2026       Tenax Therapeutics

Tenax Therapeutics, Inc. ("Tenax" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in Tenax Therapeutics, Inc. (NASDAQ: TENX), examining whether the Company may have violated the federal se...
Thu, 29.10.2026       Tenax Therapeutics

Lead Plaintiff Deadline: December 28, 2026. Investors who purchased (NASDAQ: TENX) securities between November 13, 2023 and August 7, 2026 may be eligible to recover losses.New York, New York--(Newsfile Corp. - October 29, 2026) - This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behal...
Thu, 29.10.2026       Tenax Therapeutics

Philadelphia, Pennsylvania--(Newsfile Corp. - October 29, 2026) - Berger Montague, a leading national plaintiffs' law firm, announces a class action lawsuit against Tenax Therapeutics, Inc. (NASDAQ: TENX) ("Tenax" or the "Company") on behalf of investors who purchased or otherwise acquired Tenax securities during the period from November 13, 2023 t...
Silent Ad
Wed, 28.10.2026       Tenax Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Tenax To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Tenax between November 13, 2023 and August 7, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh...
Wed, 28.10.2026       Tenax Therapeutics

Rosen Law Firm, a global investor rights law firm, announces a class action on behalf of purchasers of securities of Tenax Therapeutics, Inc. (NASDAQ: TENX) between November 13, 2023 and August 7, 2026, inclusive (the “Class Period”). Tenax is a Phase 3, development stage pharmaceutical company.For more information, submit a form, email attorney Ph...
Tue, 27.10.2026       Tenax Therapeutics

New York, New York--(Newsfile Corp. - October 27, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) on behalf of investors that purchased or otherwise acquired Tenax securities between November 13, 2023 and August 7, 2026 (the "Clas...
Tue, 27.10.2026       Tenax Therapeutics

Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Tenax Therapeutics, Inc. (NASDAQ: TENX) securities between November 13, 2023 and August 7, 2026, inclusive (the “Class Period”). Tenax is a development-stage pharmaceutical company focuse...
Tue, 01.09.2026       Tenax Therapeutics

CHAPEL HILL, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) announced today that Chris Giordano, President & Chief Executive Officer, will present at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 a.m. ET....
Sat, 29.08.2026       Tenax Therapeutics

In patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo (p = 0.0112)...
Sun, 16.08.2026       Tenax Therapeutics

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tenax Therapeutics, Inc. (“Tenax” or “the Company”) (NASDAQ: TENX) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false...
Fri, 14.08.2026       Tenax Therapeutics

A single clinical readout drove Tenax Therapeutics (NASDAQ: TENX) shares down approximately 84% to 85% shareholder after the Company disclosed that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed both its primary and key secondary endpoints. If you held TENX shares and suffered a loss, you are encouraged to click here to submit your informat...
Mon, 10.08.2026       Tenax Therapeutics

TNX-103 did not meet statistical significance on the primary endpoint of improvement in 6-minute walk distance versus placebo...
Fri, 31.07.2026       Tenax Therapeutics

Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026...
Thu, 02.07.2026       Tenax Therapeutics

CHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced it awarded inducement option awards on July 1, 2026 as material ind...
Thu, 02.07.2026       Tenax Therapeutics

Abstract recently submitted in anticipation of initial data analysis ahead of ESC...
Tue, 12.05.2026       Tenax Therapeutics

On track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026...
Fri, 08.05.2026       Tenax Therapeutics

CHAPEL HILL, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced it has awarded or will award inducement option awards between April...
Mon, 04.05.2026       Tenax Therapeutics

Mr. Healey is a seasoned pharmaceutical executive with a strong track record of successful commercial leadership experience Mr. Healey is a seasoned pharmaceutical executive with a strong track record of successful commercial leadership experience...
Wed, 22.04.2026       Tenax Therapeutics

Mr. Staab has over 25 years of financial and executive experience across the healthcare industry...
Tue, 10.03.2026       Tenax Therapeutics

Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026...
Mon, 09.02.2026       Tenax Therapeutics

Das Instrument YBO0 US88032L6056 TENAX THERAP.NEW DL-,0001 EQUITY hat seinen ersten Handelstag am 10.02.2026: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP N The instrument YBO0 US88032L6056 TENAX THERAP.NEW DL-,0001 EQUITY has its first trading date on 10.02.2026: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP N...
Wed, 04.02.2026       Tenax Therapeutics

CHAPEL HILL, N.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the Company will participate in a fireside chat at the Guggenh...
Wed, 17.12.2025       Tenax Therapeutics

Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study...
Tue, 25.11.2025       Tenax Therapeutics

CHAPEL HILL, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the following investor conferences:...
Wed, 12.11.2025       Tenax Therapeutics

Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026...
Tue, 16.09.2025       Tenax Therapeutics

Provides Patent Protection in Europe Through at Least December 2040...
Thu, 28.08.2025       Tenax Therapeutics

CHAPEL HILL, N.C., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will participate in a fireside chat at the Cantor Global Heal...
Wed, 13.08.2025       Tenax Therapeutics

Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026...
Tue, 25.03.2025       Tenax Therapeutics

Successfully Completed Private Placements with Aggregate Gross Proceeds of Approximately $125 Million to Support Advancement of Two Registrational Studies for TNX-103 in PH-HFpEF and Fund Operations through 2027...
Fri, 31.01.2025       Tenax Therapeutics

CHAPEL HILL, N.C., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced t...
Wed, 13.11.2024       Tenax Therapeutics

Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors...
Tue, 06.08.2024       Tenax Therapeutics

CHAPEL HILL, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced t...
Tue, 14.05.2024       Tenax Therapeutics

Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated...